Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016

Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016
Published Jun 22, 2016
54 pages — Published Jun 22, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016, provides in depth analysis on Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2)
- The report reviews Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targete

  
Source:
Document ID
GMDHC0089TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Overview71
Therapeutics Development83
  Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Products under Development by Stage of Development81
  Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Products under Development by Therapy Area91
  Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Products under Development by Indication101
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Pipeline Products Glance112
  Late Stage Products111
  Early Stage Products121
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Products under Development by Companies132
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Products under Development by Universities/Institutes152
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Therapeutics Assessment175
  Assessment by Monotherapy/Combination Products171
  Assessment by Mechanism of Action182
  Assessment by Route of Administration201
  Assessment by Molecule Type211
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Companies Involved in Therapeutics Development226
  Addex Therapeutics Ltd221
  Domain Therapeutics SA231
  Eli Lilly and Company241
  Johnson &Johnson251
  Merck &Co., Inc.261
  Taisho Pharmaceutical Holdings Co., Ltd.271
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Drug Profiles2811
  ADX-92639 Drug Profile281
  JNJ-40411813 Drug Profile293
  LSN-2535717 Drug Profile321
  LY-2607540 Drug Profile331
  MGS-0028 Drug Profile341
  Small Molecule to Modulate Metabotropic Glutamate Receptor 2 for Psychosis Drug Profile351
  Small Molecules to Antagonize mGlu2 for Anxiety and Depression Drug Profile361
  Small Molecules to Antagonize mGluR2 for Central Nervous System Disorders Drug Profile371
  Small Molecules to Antagonize mGluR2 for Parkinson s Disease Drug Profile381
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Dormant Projects393
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Discontinued Products421
Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) Featured News &Press Releases4310
  Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy431
  Feb 19, 2015: Addex mGluR2 NAM Demonstrates Protection in Preclinical Model of Ischemic Neuronal Death431
  Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms441
  Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression441
  Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients452
  Nov 05, 2012: Addex Therapeutics Reports Top-line Data From Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients471
  Sep 17, 2012: Addex Partner Doses First Patient In Phase II Clinical Study Of ADX71149 For Treatment Of Major Depressive Disorder Patients With Anxiety Symptoms481
  Jun 05, 2012: Janssen To Initiate Phase II Clinical Trial Of ADX71149 For Treatment Of Major Depressive Disorder With Anxiety Symptoms481
  Mar 28, 2011: Addex Partner Starts Phase IIa Clinical Trial Of ADX71149 In Schizophrenia491
  Sep 02, 2010: Addex's mGluR2 Shows Efficacy In Alzheimer s Disease Model501
  Aug 25, 2010: Addex Partner Completes ADX71149 Phase I Program511
  Jun 24, 2009: Addex Partner Starts First-Ever Clinical Trial Of An mGluR Positive Allosteric Modulator511
  Jan 17, 2005: Addex Pharmaceuticals Enters Into Collaboration With Ortho-McNeil Pharmaceutical To Develop Novel Treatments For Anxiety, Depression, Schizophrenia And Alzheimer's Disease521
Appendix532
  Methodology531
  Coverage531
  Secondary Research531
  Primary Research531
  Expert Panel Validation531
  Contact Us531
  Disclaimer541

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016" Jun 22, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Metabotropic-Glutamate-Receptor-2-mGluR2-or-GRM2-or-GPRC1B-or-MGLUR2-Pipeline-Review-H1-2016-2088-15996>
  
APA:
Global Markets Direct - Market Research. (2016). Metabotropic Glutamate Receptor 2 (mGluR2 or GRM2 or GPRC1B or MGLUR2) - Pipeline Review, H1 2016 Jun 22, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Metabotropic-Glutamate-Receptor-2-mGluR2-or-GRM2-or-GPRC1B-or-MGLUR2-Pipeline-Review-H1-2016-2088-15996>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.